{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T16:57:10Z","timestamp":1778259430237,"version":"3.51.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007109","name":"Universit\u00e0 degli Studi di Ferrara","doi-asserted-by":"publisher","award":["FAR.L-CE 2019-2022; FAR.L_medtras_CE, 2023-FAR.L-FIRD_medtras"],"award-info":[{"award-number":["FAR.L-CE 2019-2022; FAR.L_medtras_CE, 2023-FAR.L-FIRD_medtras"]}],"id":[{"id":"10.13039\/501100007109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007109","name":"Universit\u00e0 degli Studi di Ferrara","doi-asserted-by":"publisher","award":["FAR 2019-24 and FIRD 2022-24"],"award-info":[{"award-number":["FAR 2019-24 and FIRD 2022-24"]}],"id":[{"id":"10.13039\/501100007109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell'Istruzione, dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PRIN2022- n. 2022F8NS75"],"award-info":[{"award-number":["PRIN2022- n. 2022F8NS75"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Hepatocellular carcinoma (HCC) is one of the most common cancers and the third leading cause of cancer-related death worldwide. The prognosis is poor, with a median survival of 12\u201315 months in patients with advanced-stage disease. Early diagnosis and the development of new, more effective therapeutic strategies are needed to address the challenges posed by this malignancy. Although immune checkpoint inhibitors have replaced multikinase inhibitors as first-line therapy, sorafenib continues to represent a valuable option for patients with contraindications to newer treatments. Based on genome-wide RNA-seq analysis, which identified mitochondrial oxidative phosphorylation (OxPhos) and\n                    <jats:italic>Hmox1<\/jats:italic>\n                    upregulation as potential pro-survival mechanisms in sorafenib-resistant cells, we investigated whether SR9009, a synthetic agonist of the nuclear receptor REV-ERB\u03b1\/\u03b2, heme competitor, and inhibitor of mitochondrial respiration, could enhance the antitumor efficacy of sorafenib in liver cancer models. Co-treatment with SR9009 and sorafenib significantly enhanced cytotoxic effects in both mouse and human liver cancer cells. This synergistic activity was associated with increased levels of free heme and a complete inhibition of mitochondrial OxPhos. In vivo xenograft studies confirmed that the combination was effective even in sorafenib-resistant tumors. Furthermore, in a N-Nitrosodiethylamine (DEN)-induced HCC model, the combination therapy led to a reduction in size in over 90% of tumor nodules, representing a significant improvement over sorafenib alone. The combination was well tolerated, with no evident signs of acute toxicity. These findings support the concept that the efficacy of anticancer therapies can be enhanced by targeting the metabolic adaptations that tumor cells rely on for survival. Combining sorafenib with agents like SR9009, that disrupt metabolic homeostasis, may offer a promising strategy for treating advanced HCC.\n                  <\/jats:p>","DOI":"10.1038\/s41420-026-02940-3","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T07:35:40Z","timestamp":1768808140000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeting metabolic vulnerabilities: REV-ERB agonist SR9009 potentiates sorafenib efficacy in liver cancer"],"prefix":"10.1038","volume":"12","author":[{"given":"Silvia","family":"Sabbioni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Guerriero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram C.","family":"Shankaraiah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Masatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Michilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristian","family":"Bassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucilla","family":"D\u2019Abundo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farzaneh","family":"Moshiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"De Siena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edi","family":"Simoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Astolfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Gramantieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Roncarati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahaeldin K.","family":"Elamin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5752-3318","authenticated-orcid":false,"given":"Massimo","family":"Bonora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7108-6508","authenticated-orcid":false,"given":"Paolo","family":"Pinton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3788-1457","authenticated-orcid":false,"given":"Carlo M.","family":"Croce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Negrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4969-5400","authenticated-orcid":false,"given":"Elisa","family":"Callegari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"2940_CR1","doi-asserted-by":"crossref","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","DOI":"10.3322\/caac.21834"},{"key":"2940_CR2","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390.","journal-title":"N Engl J Med"},{"key":"2940_CR3","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163\u201373.","journal-title":"Lancet"},{"key":"2940_CR4","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382:1894\u2013905.","journal-title":"N Engl J Med"},{"key":"2940_CR5","doi-asserted-by":"publisher","first-page":"e412","DOI":"10.1016\/S1470-2045(20)30430-7","volume":"21","author":"X Yang","year":"2020","unstructured":"Yang X, Lin Wang D, Yang J, Zhao X. H. Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma. Lancet Oncol. 2020;21:e412.","journal-title":"Lancet Oncol"},{"key":"2940_CR6","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.annonc.2021.02.014","volume":"32","author":"A Vogel","year":"2021","unstructured":"Vogel A, Martinelli E. clinicalguidelines@esmo.org EGCEa, Committee EG. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Ann Oncol. 2021;32:801\u20135.","journal-title":"Ann Oncol"},{"key":"2940_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2025.101781","volume":"30","author":"LL Chan","year":"2025","unstructured":"Chan LL, Kwong TT, Yau JCW, Chan SL. Treatment for hepatocellular carcinoma after immunotherapy. Ann Hepatol. 2025;30:101781.","journal-title":"Ann Hepatol"},{"key":"2940_CR8","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jamaoncol.2023.2677","volume":"10","author":"S Cappuyns","year":"2024","unstructured":"Cappuyns S, Corbett V, Yarchoan M, Finn RS, Llovet JM. Critical appraisal of guideline recommendations on systemic therapies for advanced hepatocellular carcinoma: a review. JAMA Oncol. 2024;10:395\u2013404.","journal-title":"JAMA Oncol"},{"key":"2940_CR9","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, et al. AASLD practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78:1922\u201365.","journal-title":"Hepatology"},{"key":"2940_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217472","volume":"613","author":"X Jiang","year":"2025","unstructured":"Jiang X, Ge X, Huang Y, Xie F, Chen C, Wang Z, et al. Drug resistance in TKI therapy for hepatocellular carcinoma: mechanisms and strategies. Cancer Lett. 2025;613:217472.","journal-title":"Cancer Lett"},{"key":"2940_CR11","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1016\/j.bmcl.2012.04.023","volume":"22","author":"R Noel","year":"2012","unstructured":"Noel R, Song X, Shin Y, Banerjee S, Kojetin D, Lin L, et al. Synthesis and SAR of tetrahydroisoquinolines as Rev-erbalpha agonists. Bioorg Med Chem Lett. 2012;22:3739\u201342.","journal-title":"Bioorg Med Chem Lett"},{"key":"2940_CR12","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1093\/nar\/24.18.3481","volume":"24","author":"L Burke","year":"1996","unstructured":"Burke L, Downes M, Carozzi A, Giguere V, Muscat GE. Transcriptional repression by the orphan steroid receptor RVR\/Rev-erb beta is dependent on the signature motif and helix 5 in the E region: functional evidence for a biological role of RVR in myogenesis. Nucleic Acids Res. 1996;24:3481\u20139.","journal-title":"Nucleic Acids Res"},{"key":"2940_CR13","doi-asserted-by":"publisher","first-page":"12859","DOI":"10.1016\/S0021-9258(19)38238-9","volume":"265","author":"MA Lazar","year":"1990","unstructured":"Lazar MA, Hodin RA, Cardona G, Chin WW. Gene expression from the c-erbA alpha\/Rev-ErbA alpha genomic locus. Potential regulation of alternative splicing by opposite strand transcription. J Biol Chem. 1990;265:12859\u201363.","journal-title":"J Biol Chem"},{"key":"2940_CR14","doi-asserted-by":"crossref","unstructured":"Gomatou G, Karachaliou A, Veloudiou OZ, Karvela A, Syrigos N, Kotteas E. The role of REV-ERB receptors in cancer pathogenesis. Int. J Mol Sci. 2023;24:8980.","DOI":"10.3390\/ijms24108980"},{"key":"2940_CR15","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/nsmb1344","volume":"14","author":"S Raghuram","year":"2007","unstructured":"Raghuram S, Stayrook KR, Huang P, Rogers PM, Nosie AK, McClure DB, et al. Identification of heme as the ligand for the orphan nuclear receptors REV-ERBalpha and REV-ERBbeta. Nat Struct Mol Biol. 2007;14:1207\u201313.","journal-title":"Nat Struct Mol Biol"},{"key":"2940_CR16","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1126\/science.1150179","volume":"318","author":"L Yin","year":"2007","unstructured":"Yin L, Wu N, Curtin JC, Qatanani M, Szwergold NR, Reid RA, et al. Rev-erbalpha, a heme sensor that coordinates metabolic and circadian pathways. Science. 2007;318:1786\u20139.","journal-title":"Science"},{"key":"2940_CR17","doi-asserted-by":"publisher","first-page":"4466","DOI":"10.7150\/thno.42478","volume":"10","author":"W Shen","year":"2020","unstructured":"Shen W, Zhang W, Ye W, Wang H, Zhang Q, Shen J, et al. SR9009 induces a REV-ERB dependent anti-small-cell lung cancer effect through inhibition of autophagy. Theranostics. 2020;10:4466\u201380.","journal-title":"Theranostics"},{"key":"2940_CR18","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nature25170","volume":"553","author":"G Sulli","year":"2018","unstructured":"Sulli G, Rommel A, Wang X, Kolar MJ, Puca F, Saghatelian A, et al. Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence. Nature. 2018;553:351\u20135.","journal-title":"Nature"},{"key":"2940_CR19","doi-asserted-by":"publisher","first-page":"12147","DOI":"10.1073\/pnas.1904226116","volume":"116","author":"P Dierickx","year":"2019","unstructured":"Dierickx P, Emmett MJ, Jiang C, Uehara K, Liu M, Adlanmerini M, et al. SR9009 has REV-ERB-independent effects on cell proliferation and metabolism. Proc Natl Acad Sci USA. 2019;116:12147\u201352.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2940_CR20","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.omtn.2022.07.015","volume":"29","author":"E Callegari","year":"2022","unstructured":"Callegari E, Guerriero P, Bassi C, D\u2019Abundo L, Frassoldati A, Simoni E, et al. miR-199a-3p increases the anti-tumor activity of palbociclib in liver cancer models. Mol Ther Nucleic acids. 2022;29:538\u201349.","journal-title":"Mol Ther Nucleic acids"},{"key":"2940_CR21","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.bbrc.2020.10.083","volume":"534","author":"Y Li","year":"2021","unstructured":"Li Y, Xia J, Shao F, Zhou Y, Yu J, Wu H, et al. Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis. Biochem Biophys Res Commun. 2021;534:877\u201384.","journal-title":"Biochem Biophys Res Commun"},{"key":"2940_CR22","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.tem.2014.06.011","volume":"25","author":"LJ Everett","year":"2014","unstructured":"Everett LJ, Lazar MA. Nuclear receptor Rev-erbalpha: up, down, and all around. Trends Endocrinol Metab: TEM. 2014;25:586\u201392.","journal-title":"Trends Endocrinol Metab: TEM"},{"key":"2940_CR23","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1080\/07420528.2023.2207649","volume":"40","author":"Y Ni","year":"2023","unstructured":"Ni Y, Nan S, Zheng L, Zhang L, Zhao Y, Fu Z. Time-dependent effect of REV-ERBalpha agonist SR9009 on nonalcoholic steatohepatitis and gut microbiota in mice. Chronobiol Int. 2023;40:769\u201382.","journal-title":"Chronobiol Int"},{"key":"2940_CR24","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202101398R","volume":"36","author":"B Fekry","year":"2022","unstructured":"Fekry B, Ribas-Latre A, Drunen RV, Santos RB, Shivshankar S, Dai Y, et al. Hepatic circadian and differentiation factors control liver susceptibility for fatty liver disease and tumorigenesis. FASEB J. 2022;36:e22482.","journal-title":"FASEB J"},{"key":"2940_CR25","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1080\/17425255.2025.2490741","volume":"21","author":"J Wang","year":"2025","unstructured":"Wang J, Cui J, Hao T, Zhang Q, Chen Y, Guo L, et al. Regulation of cyclophosphamide induced hepatotoxicity by REV-ERBalpha modifiers. Expert Opin Drug Metab Toxicol. 2025;21:885\u201395.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2940_CR26","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/978-1-4939-9027-6_18","volume":"1928","author":"J Zhang","year":"2019","unstructured":"Zhang J, Zhang Q. Using seahorse machine to measure OCR and ECAR in cancer cells. Methods Mol Biol. 2019;1928:353\u201363.","journal-title":"Methods Mol Biol"},{"key":"2940_CR27","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1002\/1878-0261.13583","volume":"18","author":"M Pujalte-Martin","year":"2024","unstructured":"Pujalte-Martin M, Belaid A, Bost S, Kahi M, Peraldi P, Rouleau M, et al. Targeting cancer and immune cell metabolism with the complex I inhibitors metformin and IACS-010759. Mol Oncol. 2024;18:1719\u201338.","journal-title":"Mol Oncol"},{"key":"2940_CR28","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.phrs.2015.08.008","volume":"100","author":"L Ercolani","year":"2015","unstructured":"Ercolani L, Ferrari A, De Mei C, Parodi C, Wade M, Grimaldi B. Circadian clock: time for novel anticancer strategies?. Pharmacol Res. 2015;100:288\u201395.","journal-title":"Pharmacol Res"},{"key":"2940_CR29","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1038\/s41388-021-01778-6","volume":"40","author":"F Battaglin","year":"2021","unstructured":"Battaglin F, Chan P, Pan Y, Soni S, Qu M, Spiller ER, et al. Clocking cancer: the circadian clock as a target in cancer therapy. Oncogene. 2021;40:3187\u20133200.","journal-title":"Oncogene"},{"key":"2940_CR30","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jbo.2017.07.001","volume":"8","author":"J Coventon","year":"2017","unstructured":"Coventon J. A review of the mechanism of action and clinical applications of sorafenib in advanced osteosarcoma. J Bone Oncol. 2017;8:4\u20137.","journal-title":"J Bone Oncol"},{"key":"2940_CR31","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1021\/pr200790e","volume":"11","author":"VH Bull","year":"2012","unstructured":"Bull VH, Rajalingam K, Thiede B. Sorafenib-induced mitochondrial complex I inactivation and cell death in human neuroblastoma cells. J Proteome Res. 2012;11:1609\u201320.","journal-title":"J Proteome Res"},{"key":"2940_CR32","doi-asserted-by":"publisher","first-page":"15105","DOI":"10.1074\/jbc.M117.783175","volume":"292","author":"C Zhang","year":"2017","unstructured":"Zhang C, Liu Z, Bunker E, Ramirez A, Lee S, Peng Y, et al. Sorafenib targets the mitochondrial electron transport chain complexes and ATP synthase to activate the PINK1-Parkin pathway and modulate cellular drug response. J Biol Chem. 2017;292:15105\u201320.","journal-title":"J Biol Chem"},{"key":"2940_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcb.2022.151225","volume":"101","author":"J Di Gregorio","year":"2022","unstructured":"Di Gregorio J, Petricca S, Iorio R, Toniato E, Flati V. Mitochondrial and metabolic alterations in cancer cells. Eur J Cell Biol. 2022;101:151225.","journal-title":"Eur J Cell Biol"},{"key":"2940_CR34","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.ijbiomac.2019.06.180","volume":"136","author":"R Santucci","year":"2019","unstructured":"Santucci R, Sinibaldi F, Cozza P, Polticelli F, Fiorucci L. Cytochrome c: an extreme multifunctional protein with a key role in cell fate. Int J Biol Macromol. 2019;136:1237\u201346.","journal-title":"Int J Biol Macromol"},{"key":"2940_CR35","doi-asserted-by":"crossref","unstructured":"Chiang SK, Chen SE, Chang LC. The role of HO-1 and its crosstalk with oxidative stress in cancer cell survival. Cells. 2021;10:2401.","DOI":"10.3390\/cells10092401"},{"key":"2940_CR36","doi-asserted-by":"crossref","unstructured":"Ryter SW. Heme oxygenase-1: an anti-inflammatory effector in cardiovascular, lung, and related metabolic disorders. Antioxidants. 2022;11:555.","DOI":"10.3390\/antiox11030555"},{"key":"2940_CR37","doi-asserted-by":"crossref","unstructured":"Wang H, Cheng Q, Bao L, Li M, Chang K, Yi X. Cytoprotective role of heme oxygenase-1 in cancer chemoresistance: focus on antioxidant, antiapoptotic, and pro-autophagy properties. Antioxidants. 2023;12:1217.","DOI":"10.3390\/antiox12061217"},{"key":"2940_CR38","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.2174\/1381612811319150004","volume":"19","author":"FA Wagener","year":"2013","unstructured":"Wagener FA, Dankers AC, van Summeren F, Scharstuhl A, van den Heuvel JJ, Koenderink JB, et al. Heme Oxygenase-1 and breast cancer resistance protein protect against heme-induced toxicity. Curr Pharm Des. 2013;19:2698\u2013707.","journal-title":"Curr Pharm Des"},{"key":"2940_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.952114","volume":"9","author":"H Li","year":"2022","unstructured":"Li H, Song S, Tien CL, Qi L, Graves A, Nasiotis E, et al. SR9009 improves heart function after pressure overload independent of cardiac REV-ERB. Front Cardiovasc Med. 2022;9:952114.","journal-title":"Front Cardiovasc Med"},{"key":"2940_CR40","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.bbrc.2015.03.070","volume":"460","author":"S Sitaula","year":"2015","unstructured":"Sitaula S, Billon C, Kamenecka TM, Solt LA, Burris TP. Suppression of atherosclerosis by synthetic REV-ERB agonist. Biochem Biophys Res Commun. 2015;460:566\u201371.","journal-title":"Biochem Biophys Res Commun"},{"key":"2940_CR41","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/0042-6822(81)90660-7","volume":"111","author":"G Meneguzzi","year":"1981","unstructured":"Meneguzzi G, Chenciner N, Corallini A, Grossi MP, Barbanti-Brodano G, Milanesi G. The arrangement of integrated viral DNA is different in BK virus-transformed mouse and hamster cells. Virology. 1981;111:139\u201353.","journal-title":"Virology"},{"key":"2940_CR42","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nbt1051","volume":"23","author":"DH Kim","year":"2005","unstructured":"Kim DH, Behlke MA, Rose SD, Chang MS, Choi S, Rossi JJ. Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol. 2005;23:222\u20136.","journal-title":"Nat Biotechnol"},{"key":"2940_CR43","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1039\/C4MT00246F","volume":"7","author":"H Atamna","year":"2015","unstructured":"Atamna H, Brahmbhatt M, Atamna W, Shanower GA, Dhahbi JM. ApoHRP-based assay to measure intracellular regulatory heme. Metallomics. 2015;7:309\u201321.","journal-title":"Metallomics"},{"key":"2940_CR44","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.3317","volume":"12","author":"D Kim","year":"2015","unstructured":"Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. Nat Methods. 2015;12:357\u201360.","journal-title":"Nat Methods"},{"key":"2940_CR45","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nbt.3122","volume":"33","author":"M Pertea","year":"2015","unstructured":"Pertea M, Pertea GM, Antonescu CM, Chang TC, Mendell JT, Salzberg SL. StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nat Biotechnol. 2015;33:290\u20135.","journal-title":"Nat Biotechnol"},{"key":"2940_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"},{"key":"2940_CR47","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation. 2021;2:100141.","journal-title":"Innovation"},{"key":"2940_CR48","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2940_CR49","doi-asserted-by":"crossref","unstructured":"Callegari E, Elamin BK, Giannone F, Milazzo M, Altavilla G, Fornari F, et al. Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology. 2012;56:1025\u201333.","DOI":"10.1002\/hep.25747"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-02940-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-02940-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-02940-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T15:03:57Z","timestamp":1770303837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-02940-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2940"],"URL":"https:\/\/doi.org\/10.1038\/s41420-026-02940-3","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"25 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The protocols for animal testing were reviewed and approved by the Italian Ministry of Health (approval no. 701\/2017-PR, no. 645\/2021-PR and n. 337\/2025-PR).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"86"}}